medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2001, Number 2

<< Back Next >>

Rev Mex Patol Clin Med Lab 2001; 48 (2)

Current events in the antimicrobial resistance patterns in a National Medical Center

Barriga AG, Rojas ML, Peredo LVMA

Language: Spanish
References: 10
Page: 65-69
PDF size: 39.85 Kb.


ABSTRACT

The in vitro activity of cefepime was compared with that of ceftazidime, cephalotin, ceftriaxone, cefuroxime, ciprofloxacin, cloramphenicol, imipenem, meropenem, oxacilin, penicillin-G and vancomicin against 13 275 bacterial strains of diverse gramnegative and grampositive type, isolated from the same number of patients of both sexes and all ages with severe bacterial infections like: sepsis, pneumonia, cellulitis, meningitis, etc. For the identification and characterization of isolates an automatized equipment was used and a broth dilution technique for susceptibility test. Overall susceptibility rate for cefepime against all isolates was 93.5%, compared with meropenem 93.1%, imipenem 88.5%, ciprofloxacin 66.9%, cefepime was highly active against all bacteria extended beta lactamase producers.


REFERENCES

  1. Chambers HF. The changing epidemiology of Staphylococcus aureus. Emerging Infect Dis 2001; 7(2): 178-182.

  2. Rice LB. Emergence of vancomycin in resistant Enterococci. Emerging Infect Dis 2001; 7(2): 183-187.

  3. Neinstein RD. Controlling antimicrobial resistance in hospitals: Infection control and use of antibiotics. Emerging Infect Dis 2001; 7(2): 188-192.

  4. McGowan JE Jr. Economic impact of antimicrobial resistance. Emerging Infect Dis 2001; 7(2): 286-292.

  5. Richet HM, Mohammed J, McDonald CL, Jarvis WR. Building comunication networks: International Network for the study and prevention of emerging antimicrobial resistance. Emerging Infect Dis 2001; 7(2): 319-322.

  6. Tenover FC, Biddle JE, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerging Infect Dis 2001; 7(2): 327-332.

  7. Thomson KS. Controversies about extendet-spectrum and Amp C beta lactamase. Emerging Infect Dis 2001; 7(2): 333-336.

  8. Silva J, Aguilar C, Estrada MD, Echaniz G, Carnalla N, Soto A, Lopez Artuñam FJ. Susceptibility to new b-lactamase of enterobacterial extended – spectrum b-lactamase (ESBL). Producers and penicillin resistant Streptococcus pneumoniae in Mexico. Journ Chemoth 1998; 10(2): 102-107.

  9. Tzouvelekis LS, Vatopoulos AC, Katsanis G, Tzelepi E. Rare case of failure by an automated system to detect Extended-Spectrum B-lactamase in a Cephalosporin Resistant. Klebsiella pneumoniae isolate. Jour Clin Microb 1999; 37(7): 2388.

  10. Ferraro JM et al. Performance standards for antimicrobial susceptibility testing 2001; M100-S11, 21-1. National Committee for Clinical Laboratory Standards.




2020     |     www.medigraphic.com